Skip Ribbon Commands
Skip to main content
Dr Zhang Zewen

Dr Zhang Zewen

BEng (Hons), MD, MRCP (UK), MMed (Int Med)


Specialty: Medical Oncology

Sub-specialties: Gynae-Oncology, Cancer Genomic Medicine, Breast

Conditions Treated by this Doctor:
Breast Cancer, Cervical Cancer, Ovarian Cancer, Uterine Cancer.

Clinical Appointments

  • Consultant SingHealth Duke-NUS Genomic Medicine Centre
  • Consultant Division of Medical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore
  • Visiting Consultant KK Breast Centre KK Women's and Children's HospitalKK Women's and Children's Hospital

Academic Appointments

  • Clinical Instructor, Duke-NUS Graduate Medical School
  • Clinical Instructor, Yong Loo Lin School of Medicine


Dr Zhang Zewen completed senior residency training in medical oncology at SGH NCC and is currently a Medical Oncologist in NCCS sub-specializing in Breast cancer and Gynecological cancer. He has a special interest in Cancer Genetics, and is part of the Cancer Genetics Service team involved in research related to hereditary cancer predisposition syndromes, including Hereditary Breast and Ovarian Cancer and Lynch syndrome. He is also passionate towards medical education and serves as Clinical Instructor in both Duke-NUS Graduate Medical School and Yong Loo Lin School of Medicine.


Professional Appointments and Committee Memberships

  • IBRCA Forum Co-Chair, 2022 to current


  • Outstanding Resident Award (RISE), Medical Oncology, 2018
  • SingHealth Seah Cheng Siang Gold Medal in Medicine, Duke-NUS Graduate Medical School, 2013

Research Interests


  • Biological significance and prognostic relevance of peripheral blood neutrophil-to-lymphocyte ratio in soft tissue sarcoma. Chan, Jason Yongsheng & Zhang, Zewen & Chew, Winston & Tan, Grace & Lim, Chloe & Zhou, Lingyue & Goh, Wei & Poon, Eileen & Somasundaram, Nagavalli & Selvarajan, Sathiyamoorthy & Sittampalam, Kesavan & Chin, Francis & Teh, Jonathan & Tan, Mann & Soo, Khee & Teo, Melissa & Farid, Mohamad & Lee, Richard Quek. (2018). Scientific Reports. 8. 10.1038/s41598-018-30442-5. 
  • Multi-center evaluation of artificial intelligent imaging and clinical models for predicting neoadjuvant chemotherapy response in breast cancer. Qi TH, Hian OH, Kumaran AM, Tan TJ, Cong TRY, Su-Xin GL, Lim EH, Ng R, Yeo MCR, Tching FLLW, Zewen Z, Hui CYS, Xin WR, Ooi SKG, Leong LCH, Tan SM, Preetha M, Sim Y, Tan VKM, Yeong J, Yong WF, Cai Y, Nei WL; JBCR; Ai3. Breast Cancer Res Treat. 2022 May;193(1):121-138. doi: 10.1007/s10549-022-06521-7. Epub 2022 Mar 9. PMID: 35262831. 
  • COVID-19 vaccination uptake and safety profile among germline BRCA1 and BRCA2 pathogenic variant carriers in Singapore. Zhang Z, Ishak NDB, Que FVF, Chua ZY, Chan SH, Chiang J, Yie JNY. Hered Cancer Clin Pract. 2023 Apr 12;21(1):5. doi: 10.1186/s13053-023-00248-2. PMID: 37046302; PMCID: PMC10091319. 
  • Geographical, ethnic, and genetic differences in pancreatic cancer predisposition, Sherilyn Zi Hui Liew and Kwok Wing Ng and Nur Diana Binte Ishak and Suat Ying Lee and Zewen Zhang and Jianbang Chiang and Joanne Yuen Yie Ngeow, Chinese Clinical Oncology, 2023

Research Trials